BioMaxima (944) Stock Overview

BioMaxima S.A. manufactures and distributes microbiological media, reagents, and equipment for in vitro diagnostics in Poland. Its primary products include analyzers and diagnostic reagents for testing the biochemical parameters of blood and other body fluids; systems for the determination of drug resistance of microorganisms; quick diagnostic tests for detecting infectious diseases, cancer markers, heart attack markers, and addictive substances and readers; urine analysis systems; hematology analyzers and reagents; ionselective analyzers and reagents; reagents and immunological analyzers of cardiac markers; glucometers for professional use; and analyzers for gasometric tests and critical blood parameters tests. The company also provides surfaces and air controls; antibiotics discs and MIC strips; and chromogenic, dehydrated, and prepared culture media; additives and supplements for media; microbank microorganism storage systems; and veterinary products. In addition, it engages in the devices for microbiological analysis; molecular biology products, including media for inactivating and transporting samples; and training activities. The company supplies its products to approximately 1,800 laboratories in Poland, as well as exports in the international markets. BioMaxima S.A. was founded in 1997 and is headquartered in Lublin, Poland.